HAEMONETICS CORP — Director's Dealing 2012

May 21, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2012-05-17

Reporting Person: GELBMAN RONALD G (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-05-17	Common Stock	S	2473.0	$71.49	Disposed	11386.0	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Qualified Stock Option (right to buy)	$22.555	2013-04-15	Common Stock (6000.0)	6000.0	Direct
Non-Qualified Stock Option (right to buy)	$26.105	2014-05-05	Common Stock (6000.0)	6000.0	Direct
Non-Qualified Stock Option (right to buy)	$44.74	2015-09-02	Common Stock (6000.0)	6000.0	Direct
Non-Qualified Stock Option (right to buy)	$49.92	2014-08-01	Common Stock (4592.0)	4592.0	Direct
Non-Qualified Stock Option (right to buy)	$52.76	2013-05-05	Common Stock (6000.0)	6000.0	Direct
Non-Qualified Stock Option (right to buy)	$54.48	2017-07-29	Common Stock (4290.0)	4290.0	Direct
Non-Qualified Stock Option (right to buy)	$58.46	2018-07-31	Common Stock (5664.0)	5664.0	Direct
Non-Qualified Stock Option (right to buy)	$59.44	2016-07-30	Common Stock (5879.0)	5879.0	Direct
Non-Qualified Stock Option (right to buy)	$68.81	2018-07-21	Common Stock (3559.0)	3559.0	Direct

Footnotes

F1: Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.

F2: Grant to reporting person of right to buy shares of common stock exercisable immediately.

F3: Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant.